Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

10 Sep 2014

Study could lead to improvements in outcomes for women with triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

8 Sep 2014

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

4 Sep 2014

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.

26 Aug 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

7 Aug 2014

Repurposed drug used to treat ovarian cancer gives positive results

A repurposed drug originally used to treat ovarian cancer saw positive results for patients with advanced peritoneal cancers during a phase I clinical trial at The University of Kansas Cancer Center.

5 Aug 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates.

23 Jul 2014

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics Biotech Inc. today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045).

8 Jul 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

24 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It's the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA).

From COOK MEDICAL INC. 5 Jun 2014

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

2 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

Paclitaxel News and Research

Further Reading

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Repurposed drug used to treat ovarian cancer gives positive results

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

CRIPTO1 role in TKI resistance elucidated

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

SLU researchers discover pain pathway and potential way to block it

New treatment for ovarian cancer can improve response rates

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Ovarian cancer patients with molecular subtypes benefit from bevacizumab

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News